Insight Resource Library Tap into Gubra’s vast production of publications, webinars, videos and posters to get the latest knowledge and insights within our focus areas: obesity, diabetes, MASH, CKD, IPF and IBD. Filtered (38) Filters Reset all × Alcoholic steatohepatitis × Real-time food intake/activity analysis × Gut biopsy × Search × Resource type Data presentation (0) Poster (1) Publication (37) 3D imaging video (0) Webinar (0) Category × Disease model (222) Cardiovascular disease (11) AngII mouse (2) DIO-ApoE-KO mouse (1) DIO-LDLR-KO mouse (4) DIO-PCK9-AAV mouse (1) Isoprenaline-induced cardiomyopathy (1) Cholangiopathy (1) Bile duct ligation (BDL) mouse (1) Mdr2-KO mouse (1) CNS disease (39) Alzheimer's disease models (9) CNS activation (12) Drug distribution (6) Gene expression (1) Gene therapy (1) Parkinson's disease models (6) Diabetes (33) db/db mouse (17) Non-obese diabetic (NOD) mouse (4) ZDF rat (10) Inflammatory bowel disease (3) Acute DSS-IBD mouse (0) Chronic DSS-IBD mouse (3) Idiopathic pulmonary fibrosis (7) BLEO-IPF mouse (4) Chronic BLEO-IPF mouse (2) HFD-BLEO-IPF mouse (0) Kidney disease (33) Acute kidney injury (4) Bilateral ischemia reperfusion injury (bIRI) mouse (1) Unilateral ischemia reperfusion injury (uIRI) mouse (3) Chronic kidney disease (18) Anti-GBM glomerulonephritis mouse (2) Adenine diet-induced (ADI) nephropathy mouse (5) Polycystic kidney disease (PCK) rat (1) Unilateral ureteral obstruction (UUO) mouse (4) 5/6 nephrectomy (Nx) rat (3) Diabetic kidney disease (17) db/db-UNx mouse (1) ReninAAV UNx db/db mouse (11) ZSF-1 rat (0) Knock-out mouse models (8) Metabolic dysfunction-associated steatohepatitis (76) GAN DIO-MASH mouse (30) GAN DIO-MASH-HCC mouse (8) GAN ob/ob-MASH mouse (5) CDAA-HFD mouse (9) CDAA-HFD rat (10) AMLN DIO-MASH mouse (18) AMLN ob/ob-MASH mouse (13) Obesity (51) Bariatric surgery (10) DIO mouse (22) DIO rat (14) ob/ob mouse (8) Therapeutic Area (241) Alzheimer's disease (13) Alcoholic steatohepatitis (2) Cardiovascular disease (10) Chronic kidney disease (28) Cholangiopathy (1) Diabetes (55) Diabetic cardiomyopathy (2) Diabetic kidney disease (18) Hepatocellular carcinoma (6) Idiopathic pulmonary fibrosis (7) Inflammatory bowel disease (3) Metabolic dysfunction-associated steatohepatitis (84) Obesity (80) Parkinson's disease (8) Target (149) Alpha-synuclein (1) Autotaxin (1) Beta amyloid (4) Acetyl-CoA carboxylase (3) Amylin receptor (4) Angiotensin converting enzyme (ACE) (5) AMPK (1) ASBT (2) CB1 receptor (5) CCK receptor (4) D2 receptor (3) DPP-IV (2) Fatty acid synthase (1) FGF receptor-1 (3) FXR (13) GCC receptor (1) GFRAL (1) Ghrelin receptor (3) GIP receptor (4) GLP-1 receptor (73) GLP-2 receptor (5) Glucagon receptor (5) GPR119 (0) GPR120 (1) G-protein coupled receptor 10 (GPR10) (1) HSD17b13 (1) 5-HT2C receptor (3) IL-1beta receptor (1) Insulin receptor (2) mARC1 (1) MC4 receptor (4) Monoamine transporter (2) Leptin receptor (1) Neuropeptide FF receptor type 2 (1) Neurotensin receptor (1) Nicotinic acetylcholine receptor (1) NPY receptor (2) NMU receptor (2) Paraoxonase-2 (1) PCSK9 (1) PICK1 (1) PPAR (23) PSD-95 (1) Renin–angiotensin system (3) Secretin receptor (1) SGLT-2 (5) TAAR1 (1) TGF-beta (7) TGR5 (2) THR-ß receptor (5) Y2 receptor (3) Compound (146) Aducanumab biosimilar (4) Adeno-associated virus (AAV)-mediated gene therapy (1) A3907 (2) Adrenomedullin (2) Alk5 inhibitor (6) ALT-801 (1) Amylin (3) Amylin receptor agonist (1) BLD-0409 (1) Bromocriptine (2) CHS-131 (1) Captopril (1) Cilofexor (1) Cotadutide (1) DA-1241 (1) Dapagliflozin (2) Dietary intervention (4) Exenatide (9) Elafibranor (10) Empagliflozin (4) Exendin-4 analogues (3) FGF21 (3) Firsocostat (3) GDF15 analogues (1) Ghrelin (1) GIP receptor agonist (1) GIPRA (1) GIP receptor antagonist (1) Glibenclamide (1) GLP-1 (5) GLP-1 receptor agonist (5) GLP-2 (1) Glucagon receptor agonist (1) Glucose-dependent insulinotropic polypeptide (GIP) (1) Guanylin (1) GUB06-046 (1) GUB08-248 (1) GUB09-123 (1) GUB09-145 (2) GUB08251 (1) GUB021794 (1) GUBamy (1) GS-834356 (1) HSD17b13 inhibitor (1) HSG4113 (1) Icosabutate (1) ID166 (0) Insulin (1) INT-767 (4) INT-787 (0) Lanifibranor (10) LEAP-2 (2) Leptin (1) Linagliptin (5) Liraglutide (30) Lisinopril (5) Lorcaserin (3) MEDI0382 (1) mPD95 (1) Neuromedin U (2) Neurotensin (1) Neurturin (1) Nicotine (1) Obeticholic acid (11) Oxyntomodulin (1) PYY3-36 (4) Prolactin-releasing peptide (1) Resmetirom (7) Rimonabant (4) Rosiglitazone (2) S961 (1) Salmon calcitonin (1) SEFA-1024 (1) Seladelpar (2) Semaglutide (31) SER140 (1) Setmelanotide (3) Sibutramine (4) TAAR1 agonists (1) Taspoglutide (1) Teduglutide (2) TVB-3664 (1) UCCB01-147 (1) Uroguanylin (1) Vutiglabridin (1) Y2 receptor agonist (1) ZP3022 (3) Method/Endpoint (264) 3D imaging (56) Adeno-associated virus (AAV)-mediated gene delivery (14) Atherosclerotic plaques (3) Beta-cell mass (12) Blood pressure (1) Body composition (11) Body weight (122) Blood biochemistry (83) Bariatric surgery (12) Bioinformatics (105) c-Fos activation (19) Clinical trial (2) Conditioned taste aversion test (1) Drug discovery (25) Drug distribution (11) Energy expenditure monitoring (4) Echocardiography (ECG) (3) Flow cytometry (1) Gut biopsy (6) Glomerular filtration rate (GFR) (8) Gastric emptying (3) Gut morphometry (12) Glucose-stimulated insulin secretion (GSIS) (1) Histopathology score (79) Heart morphometry (5) Intraperitoneal glucose tolerance test (IPGTT) (7) Image analysis (149) Immunohistochemistry (IHC) (143) In situ hybridization (ISH) (14) Insulin tolerance test (ITT) (2) Kidney biopsy (2) Kidney morphometry (24) Lung functional test (5) Light sheet fluorescence microscopy (LSFM) (59) Liver biopsy (67) Liver morphometry (64) Lung biochemistry (4) Laser-capture microdissection (LCM) (9) Magnetic resonance imaging (MRI) (2) Microbiomics (5) Micro-computed tomography (micro-CT) (1) Neurobehavior (6) Next-generation sequencing (49) Nephrectomy (14) Oral glucose tolerance test (OGTT) (20) Pancreatectomy (1) Peptide chemistry (14) Pharmacokinetics (9) Proteomics (1) qPCR (1) Real-time food intake/activity analysis (32) Receptor binding (3) Roux-en-Y gastric bypass (RYGB) (8) RNA sequencing (84) Single-cell RNA sequencing (3) Single-nucleus RNA sequencing (6) siRNA (1) StreaMLine (1) Surgery (12) Spirometry (5) Stereology (29) Stereotaxic injection (2) Ultrasound imaging (1) Urine biochemistry (12) Vasculature (2) Vertical sleeve gastrectomy (1) Western Blotting (1) Whole-body plethysmography (4) Whole-brain in situ hybridization (4) Species (218) Hamster (1) Human (30) Mouse (176) Minipig (2) Non-human primate (3) Pig (3) Rat (34) Show (38) Cancel Sort result Default sorting By title: alphabetical By title: reverse By date: oldest first By date: newest first Reset all × Alcoholic steatohepatitis × Real-time food intake/activity analysis × Gut biopsy × 38 resource library items found PosterDistinct metabolic effects of semaglutide and resmetirom at thermoneutrality in diet-induced obese mice PublicationStructurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease PublicationLEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men PublicationEffects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis PublicationHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH PublicationLipidated PrRP31 metabolites are long acting dual GPR10 and NPFF2 receptor agonists with potent body weight lowering effect PublicationCharacterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice PublicationChronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism PublicationActivation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis PublicationInterferon lambda 4 genotype and pathway in alcoholic hepatitis PublicationCharacterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in db/db mice Publication3D quantification of changes in pancreatic islets in mouse models of diabetes type I and II PublicationGut mucosal gene expression and metabolic changes after Roux-en-Y gastric bypass surgery PublicationIdentification and metabolic profiling of a novel human gut-derived LEAP2 fragment PublicationLow interleukin-22 binding protein is associated with high mortality in alcoholic hepatitis and modulates interleukin-22 receptor expression PublicationResolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis PublicationActivation of adenosine monophosphate-activated protein kinase reduces the onset of diet-induced hepatocellular carcinoma in mice PublicationIncretin combination therapy for the treatment of non-alcoholic steatohepatitis PublicationGlobal transcriptome analysis of rat hypothalamic arcuate nucleus demonstrates reversal of hypothalamic gliosis following surgically and diet induced weight loss PublicationMetabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice PublicationInvestigating intestinal glucagon after Roux-en-Y gastric bypass surgery PublicationThe role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach PublicationAdrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice PublicationNovel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice Load More For further information Contact us Gubra Hørsholm Kongevej 11B 2970 Hørsholm Denmark +45 3152 2650